Our Company
Press Release Archive
-
JANSSEN RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SIRUKUMAB BIOLOGICS LICENSE APPLICATION
-
Research Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health NeedsPeople Who Are on The Frontlines of Trauma are Unaware of Their Risk Factors for Serious Health Conditions
-
NEW TWO-YEAR TREMFYA™ (GUSELKUMAB) DATA SHOW PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS ACHIEVED CONSISTENT RATES OF SKIN CLEARANCEMore than 80 percent of patients receiving TREMFYA™, including patients transitioned from Humira® to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week ...
-
JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNIONPending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23
-
Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight InfluenzaJanssen and Biomedical Advanced Research and Development Authority (BARDA) join forces to accelerate new therapies and vaccines to protect communities against the threat of a pandemic
-
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
-
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate CancerFiling Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA® in Combination with Prednisone and Androgen Deprivation Therapy (ADT)
-
Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and GeographiesShark Tank's Daymond John to Judge the First Champions of Science "What's New?" Challenge Multifaceted Platform to Broaden Public Engagement in Science
-
Johnson & Johnson Consumer Inc. Debuts New Scientific Data at the European Academy of Dermatology and Venerology Annual MeetingConsumer sector demonstrates leadership with new research in areas such as skin microbiome, light therapy, anti-ageing and hair loss
-
Janssen to Discontinue Hepatitis C Development ProgramViral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B